| scholarly article | Q13442814 |
| P50 | author | Koleka Mlisana | Q46535610 |
| P2093 | author name string | H Li | |
| G M Shaw | |||
| S S Abdool Karim | |||
| C Williamson | |||
| L Morris | |||
| CAPRISA 002 Study Team | |||
| E S Gray | |||
| F Bibollet-Ruche | |||
| F Treurnicht | |||
| I A Choge | |||
| J M Decker | |||
| N Leseka | |||
| P L Moore | |||
| P2860 | cites work | Antigenic conservation and immunogenicity of the HIV coreceptor binding site | Q36403587 |
| Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication | Q39485916 | ||
| Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma | Q40311562 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains | Q40621073 | ||
| Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies | Q40682865 | ||
| The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. | Q45662866 | ||
| Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes | Q48088168 | ||
| Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome | Q24648628 | ||
| Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates | Q27629806 | ||
| The antigenic structure of the HIV gp120 envelope glycoprotein | Q28274698 | ||
| Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B | Q28469023 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes | Q29616210 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. | Q30423779 | ||
| Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes | Q30706865 | ||
| An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. | Q33784679 | ||
| The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner | Q33883936 | ||
| A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences | Q34647858 | ||
| Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 | Q34648079 | ||
| Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa | Q35140032 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 6187-6196 | |
| P577 | publication date | 2007-04-04 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | |
| P478 | volume | 81 |
| Q33547451 | 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms |
| Q36483956 | 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response |
| Q90434609 | A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies |
| Q34463861 | A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop |
| Q35077704 | Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic |
| Q58038022 | Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level |
| Q38342167 | Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop |
| Q35077677 | An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum |
| Q37033400 | Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals |
| Q64061234 | Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens |
| Q35641369 | Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency |
| Q33826951 | Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q92538619 | Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway |
| Q34982646 | Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses |
| Q39108751 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development |
| Q30375834 | Appreciating HIV type 1 diversity: subtype differences in Env. |
| Q40145762 | Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope |
| Q35956940 | Association of enhanced HIV-1 neutralization by a single Y681H substitution in gp41 with increased gp120-CD4 interaction and macrophage infectivity |
| Q37010878 | Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies |
| Q28751926 | Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys |
| Q36845710 | Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection |
| Q34008741 | B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses |
| Q33373664 | B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4. |
| Q35689608 | Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions |
| Q35192937 | Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site |
| Q27675131 | Broad and potent neutralization of HIV-1 by a gp41-specific human antibody |
| Q33417195 | Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope |
| Q37410792 | Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region |
| Q38707583 | Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response |
| Q35894094 | Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort |
| Q38065391 | Broadly neutralizing antibodies against HIV-1: templates for a vaccine |
| Q46683819 | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning |
| Q36753653 | Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q34300812 | Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection |
| Q53825583 | Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. |
| Q100490986 | Common evolutionary features of the envelope glycoprotein of HIV-1 in patients belonging to a transmission chain |
| Q35861256 | Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research |
| Q90343014 | Comparison of the antiviral activity of the microbicide candidate griffithsin and its tandemers derivatives against different modes of HIV-1 transmission |
| Q36694111 | Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop |
| Q36628606 | Correlates of relative resistance against low-dose rectal simian immunodeficiency virus challenges in peripheral blood mononuclear cells of vaccinated rhesus macaques |
| Q37256644 | Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1 |
| Q36057328 | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet |
| Q37069837 | Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. |
| Q42207794 | Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner |
| Q58763247 | Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers |
| Q24612992 | Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes |
| Q42850455 | Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity |
| Q33410222 | Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection |
| Q36194234 | Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth |
| Q36000736 | Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape |
| Q93037487 | Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection |
| Q39245066 | Effector mechanisms of humoral immunity to porcine reproductive and respiratory syndrome virus |
| Q28732438 | Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein |
| Q33558407 | Envelope vaccination shapes viral envelope evolution following simian immunodeficiency virus infection in rhesus monkeys |
| Q44775993 | Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. |
| Q33504599 | Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways |
| Q55359818 | Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains. |
| Q36388754 | Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape |
| Q34478071 | Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject |
| Q35140461 | Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum |
| Q24653373 | Evolution of proviral gp120 over the first year of HIV-1 subtype C infection |
| Q40794254 | Exploring the benefits of antibody immune response in HIV-1 infection using a discrete model. |
| Q21245045 | Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection |
| Q37033294 | Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection |
| Q33899181 | Fc receptor-mediated antiviral antibodies |
| Q43611862 | Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies |
| Q34962907 | Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaques |
| Q46454115 | HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage |
| Q57071746 | HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth |
| Q21559422 | HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC |
| Q33703451 | HIV neutralizing antibodies: clinical correlates and implications for vaccines |
| Q28487168 | HIV-1 Env C2-V4 diversification in a slow-progressor infant reveals a flat but rugged fitness landscape |
| Q56913214 | HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes |
| Q27497560 | HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV |
| Q59811711 | HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth |
| Q33842522 | HIV-1 maternal and infant variants show similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype |
| Q37484124 | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study |
| Q34350944 | HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression |
| Q36334990 | HIV-1 subtype C superinfected individuals mount low autologous neutralizing antibody responses prior to intrasubtype superinfection |
| Q33614208 | HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection |
| Q40159913 | HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection |
| Q38541824 | Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles |
| Q37471315 | High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination |
| Q47552258 | High-Resolution Sequencing of Viral Populations During Early SIV Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses. |
| Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q36423897 | Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection |
| Q37051645 | Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma |
| Q39668082 | Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins |
| Q34455457 | Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models |
| Q59357079 | Immune Correlate-Guided HIV Vaccine Design |
| Q34120088 | Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus |
| Q41925820 | Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. |
| Q34823713 | Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models |
| Q36673288 | Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion |
| Q36804634 | Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination |
| Q34009730 | In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies |
| Q34937404 | In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth |
| Q38658529 | Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site |
| Q33916676 | Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines |
| Q27312171 | Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41 |
| Q33614605 | Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates |
| Q34848486 | Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia |
| Q34042758 | Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting |
| Q33912373 | Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual |
| Q33504604 | Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection |
| Q90423874 | Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost |
| Q35077797 | Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies |
| Q36107520 | Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin |
| Q41752911 | Mathematical model of multivalent virus-antibody complex formation in humans following acute and chronic HIV infections |
| Q35192782 | Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. |
| Q53695792 | Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11. |
| Q35161426 | Molecular characterization of HIV-1 subtype C gp-120 regions potentially involved in virus adaptive mechanisms |
| Q36249053 | Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially |
| Q36760049 | Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies |
| Q36099045 | N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization |
| Q34100200 | Neuropathogenic SIVsmmFGb genetic diversity and selection-induced tissue-specific compartmentalization during chronic infection and temporal evolution of viral genes in lymphoid tissues and regions of the central nervous system |
| Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
| Q30537665 | Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China |
| Q37519312 | Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? |
| Q84325970 | Neutralizing antibodies in SIV control: co-impact with T cells |
| Q36246315 | Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope |
| Q34083235 | Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India |
| Q33877434 | Nonpathogenic simian immunodeficiency virus infection of sooty mangabeys is not associated with high levels of autologous neutralizing antibodies |
| Q43096886 | Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. |
| Q37530545 | Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. |
| Q35867981 | Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection. |
| Q36281817 | Phenotypic Correlates of HIV-1 Macrophage Tropism |
| Q41872618 | Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America |
| Q33479167 | Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q64063774 | Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies |
| Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
| Q35665765 | Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes |
| Q35077483 | Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency. |
| Q39610645 | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 |
| Q35973587 | Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys |
| Q33725673 | Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors |
| Q37039116 | Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression |
| Q35603504 | Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. |
| Q26823603 | Recent strategies targeting HIV glycans in vaccine design |
| Q34709433 | Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex |
| Q34042642 | Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections |
| Q93122251 | Reduced frequency of HIV superinfection in a high-risk cohort in Zambia |
| Q36155365 | Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses |
| Q100295640 | Selection and immune recognition of HIV-1 MPER mimotopes |
| Q35943521 | Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site |
| Q41876895 | Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques |
| Q34982715 | Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies |
| Q35508247 | Short communication decreased incidence of dual infections in South african subtype C-infected women compared to a cohort ten years earlier |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q36446733 | Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q36246403 | Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. |
| Q37409244 | Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site |
| Q34312037 | Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus |
| Q33664910 | Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response |
| Q39108730 | Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem |
| Q27000889 | The Antibody Response against HIV-1 |
| Q34485260 | The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter |
| Q38243948 | The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development |
| Q42314454 | The HIV-1 transmission bottleneck |
| Q54987756 | The Janus Face of Follicular T Helper Cells in Chronic Viral Infections. |
| Q46180922 | The Neutralizing Antibody Response To the HIV-1 Env Protein. |
| Q36483346 | The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection |
| Q33504607 | The cat and mouse of HIV-1 antibody escape |
| Q37099851 | The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions |
| Q37789346 | The humoral response to HIV-1: new insights, renewed focus. |
| Q34614862 | The immune response during acute HIV-1 infection: clues for vaccine development |
| Q35743210 | The lectins griffithsin, cyanovirin-N and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells |
| Q36497712 | The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q34017550 | The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8. |
| Q35943810 | UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C |
| Q52567903 | Ultradeep single-molecule real-time sequencing of HIV envelope reveals complete compartmentalization of highly macrophage-tropic R5 proviral variants in brain and CXCR4-using variants in immune and peripheral tissues. |
| Q34441935 | Unique C2V3 sequence in HIV-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization |
| Q41932027 | Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes |
| Q60959639 | V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity |
| Q61448102 | VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120 |
| Q34203163 | Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection |
| Q35034268 | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes |
| Q27025177 | Virological features associated with the development of broadly neutralizing antibodies to HIV-1 |
| Q45357217 | Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41. |
| Q35192660 | epitopes immediately below the base of the V3 loop of gp120 as targets for the initial autologous neutralizing antibody response in two HIV-1 subtype B-infected individuals |
Search more.